LDS/Medical Tests/Mycophenolic Acid, Serum

Mycophenolic Acid, Serum

Successful organ transplantation depends on suppressing the recipient’s immune system to prevent rejection of the donor graft. Mycophenolic acid (MPA) is a potent immunosuppressant derived from Penicillium species and is widely used in transplant medicine. MPA selectively inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme essential for de novo synthesis of guanosine nucleotides. This pathway is particularly important for the proliferation of T and B lymphocytes, as these cells rely heavily on de novo rather than salvage nucleotide synthesis. By blocking IMPDH, MPA inhibits the proliferation of lymphocytes, reducing antibody production and cytotoxic T-cell responses.

MPA is typically administered as the prodrug mycophenolate mofetil (MMF), which is hydrolyzed in vivo to the active compound. The narrow therapeutic window of MPA makes therapeutic drug monitoring essential. Excessive drug levels increase the risk of severe infections and bone marrow suppression, while subtherapeutic levels may result in graft rejection, does monitoring MPA in treated patient with MPA is essential.
In addition to its use in transplant medicine, MPA has also been explored as an adjunct to antiretroviral therapy in HIV/AIDS. Its ability to inhibit IMPDH and reduce intracellular guanosine pools leads to impaired T-cell activation and may reduce the availability of host cells susceptible to HIV infection. While still under investigation, this mechanism supports its potential as an immune-modulating agent beyond transplant applications.

  • Monitoring mycophenolic acid levels in blood to ensure optimum immunosuppression
  • Aids in balancing the risk of graft rejection with the risk of infection or toxicity
Steady-state serum levels within the reference range suggest appropriate immunosuppressive therapy. Levels above 3.5 mcg/mL indicate potential over-immunosuppression and may be associated with increased risk for infections, gastrointestinal toxicity, or hematologic suppression. In such cases, dose adjustment may be necessary. Subtherapeutic levels (<1.0 mcg/mL) could place the patient at risk for graft rejection or disease flare and may require dosage increase.

1.0 – 3.5 mcg/mL

Liquid chromatography–tandem mass spectrometry (LC-MS/MS).

Serum, Red top tube.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 30 days
Lymphocyte proliferation panel.
3 to 5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login